Last updated 2026-07-26
- Raised $18M Series E led by Star Ventures, Apr 2011
- Raised $6M Series D led by Star Ventures, Jan 2006
- Raised $7M Series C, Jan 2004
Total raised
$44.4M
Last: Undisclosed Round 2011-05
Stage
Mature
Founded
1996
Headcount
26
HQ
Petah Tikva, Israel
Sector
Health Tech & Life Sciences
About
OrSense is a medical device company that develops and commercializes non-invasive monitoring systems for continuous and spot measurements of hemoglobin, oxygen saturation, glucose, and other blood parameters. The company's proprietary Occlusion Spectroscopy technology, also known as SpectOLight, utilizes a ring-shaped finger sensor and occlusion-based optical measurement to provide accurate, painless, and non-invasive readings. Their products, including the NBM-200, are FDA and CE approved and are used in hospitals, blood donation centers, physician offices, and for various health applications worldwide.
Funding history · 6 rounds · $44.4M total
2011-04
E Round
$18.0M
★ Star Ventures★ Lewis Trust Group★ Israel HealthCare Ventures
2006-01
D Round
$6.0M
★ Star Ventures★ Lewis Trust Group★ Israel HealthCare Ventures
2004-01
C Round
$7.0M
2001-07
Grant
$1.2M
2001-07
B Round
$8.2M
★ Star Ventures★ Israel HealthCare Ventures
1969-12
A Round
$4.0M
Headcount over time
From 25 (2018-09) to 26 (2026-03) · +1 (+4%) · 18 points · source: Finder history + radar grounding
Q&A
- What is OrSense's primary business?
- OrSense is a medical device company that develops and commercializes non-invasive monitoring systems for continuous and spot measurements of hemoglobin, oxygen saturation, glucose, and other blood parameters.
- What is OrSense's core technology?
- OrSense utilizes proprietary Occlusion Spectroscopy technology, also known as SpectOLight, which uses a ring-shaped finger sensor and occlusion-based optical measurement for accurate, painless, and non-invasive readings.
- What was OrSense's most recent funding round?
- Investors included Israel Healthcare Ventures and Star Ventures.
- When did OrSense receive FDA market clearance for its NBM-200 system?
- In May 2019, the FDA granted market clearance for the OrSense NBM200, making it the first noninvasive hemoglobin system cleared for use in blood donation centers.
- Where is OrSense headquartered?
- OrSense is headquartered in Petah Tikva, Israel.
- What is the total amount of funding OrSense has raised to date?
- OrSense has raised a total of $44,400,000.
- In which countries does OrSense operate or deliver systems?
- OrSense has delivered its first systems in Mexico and also has an office in Raleigh, United States.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Monitors
Technologies
SensingOpticPlatforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
spectroscopysensorsmeasurementsdiabetesmonitoringhospitalsmedical-devicesnon-invasivehealthcare-providerssoftware-applicationsoptronicsmedical-technologies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | orsense.com |
|---|---|
| linkedin.com/company/105808 | |
| YouTube | youtube.com/channel/UCzNlJg0qFOXSk3_cBgeH7_g |
Identifiers & details
| Founded | 1996 |
|---|---|
| Employees (exact) | 26 |
| Offices | Raleigh |
Radar intelligence
Patents
| EPO | 25 |
|---|
Publications (Crossref)
| Works | 4 |
|---|
Web history (Wayback)
| Domain | orsense.com |
|---|
Certificate / subdomain footprint
| Subdomains | 16 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512389214 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1996-10-29 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | הנחושת 6 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |